Rapamycin (Sirolimus) Compounding Legal Status: FDA Approval, Off-Label Use, and Pharmacy Rules

FDA Approval History of Sirolimus

The FDA first approved sirolimus on September 15, 1999, under New Drug Application (NDA) 021083 for the prophylaxis of organ rejection in renal transplant recipients aged 13 years and older [1]. Wyeth Pharmaceuticals (now Pfizer) developed the drug after its discovery from a soil bacterium (Streptomyces hygroscopicus) on Rapa Nui (Easter Island) in 1972. The compound's mechanism of action, inhibition of the mammalian target of rapamycin (mTOR), became one of the most studied pathways in cell biology over the following decades.

A second indication followed in May 2015 when the FDA approved sirolimus for the treatment of lymphangioleiomyomatosis (LAM), a rare progressive lung disease affecting primarily women [2]. This approval was based on the MILES trial (N=89), which demonstrated stabilization of FEV1 decline and improvement in quality of life measures compared to placebo over 12 months. The drug remains available as 0.5 mg, 1 mg, and 2 mg tablets and as a 1 mg/mL oral solution under the brand name Rapamune.

Generic sirolimus tablets became available in 2014 after patent expiration. Multiple manufacturers now produce generic versions, which has reduced costs and broadened access. The FDA's Drugs@FDA database lists over a dozen approved generic applications for sirolimus tablets [3].

What the Sirolimus Label Actually Says

The current FDA-approved label restricts sirolimus to two indications: renal transplant rejection prophylaxis (in combination with cyclosporine and corticosteroids) and LAM [1]. The label carries a boxed warning. It states that only physicians experienced in immunosuppressive therapy and management of organ transplant patients should use sirolimus for the transplant indication. The boxed warning also notes increased susceptibility to infection and possible development of lymphoma.

For the transplant indication, the label recommends an initial loading dose of 6 mg followed by 2 mg daily, with trough level monitoring targeting 12 to 20 ng/mL in the first year when used with cyclosporine [1]. After cyclosporine withdrawal (typically at 2 to 4 months post-transplant), target troughs shift to 12 to 24 ng/mL.

For LAM, the label recommends a starting dose of 2 mg daily, adjusted to maintain trough concentrations between 5 and 15 ng/mL [2]. This is important context for clinicians. The doses being explored in longevity medicine (typically 1 to 6 mg once weekly) are far below the daily immunosuppressive regimens on the label.

Key label warnings include immunosuppression-related infections, hyperlipidemia, impaired wound healing, and interstitial lung disease [4]. The label also notes that sirolimus should not be used simultaneously with strong CYP3A4 inhibitors (such as ketoconazole, voriconazole, or clarithromycin) or inducers (such as rifampin) without dose adjustment.

Compounding Regulations: 503A and 503B Pathways

Compounding pharmacies in the United States operate under two primary regulatory frameworks established by the Drug Quality and Security Act (DQSA) of 2013 [5]. Understanding both pathways is necessary for patients and prescribers considering compounded sirolimus.

Section 503A pharmacies are traditional compounding pharmacies that prepare medications based on individual patient prescriptions. Under 503A, a pharmacy may compound sirolimus if a licensed prescriber writes a patient-specific prescription, the pharmacy does not compound "essentially a copy" of a commercially available product without a clinical change (such as a different dosage form, strength, or removal of an allergen), and the pharmacy complies with state board of pharmacy regulations [5].

Section 503B outsourcing facilities may compound without patient-specific prescriptions and can distribute larger quantities, but they must register with the FDA, comply with current good manufacturing practice (cGMP) requirements, and submit to FDA inspections [5]. These facilities can produce compounded sirolimus in batches.

Sirolimus does not appear on the FDA's list of drugs that present "demonstrable difficulties" for compounding, nor on the withdrawn or removed list [6]. This means neither 503A nor 503B pharmacies face a categorical FDA barrier to compounding sirolimus. The practical result: compounded sirolimus is legally available in formulations and strengths not commercially offered (for example, low-dose capsules of 0.5 mg or less, topical preparations, or customized oral suspensions).

State-level regulations vary. Some state boards of pharmacy impose additional restrictions on compounding or require specific documentation for compounds based on commercially available drugs. Prescribers should verify their state board's current position. The FDA's compounding page provides federal-level guidance and updated lists [6].

Off-Label Use and the Longevity Medicine Context

Sirolimus has attracted significant clinical interest for potential anti-aging and geroprotective effects based on preclinical evidence in multiple organisms and a growing number of human trials. This is off-label use. No FDA-approved indication exists for longevity or aging.

Off-label prescribing is legal in the United States. A physician may prescribe any FDA-approved drug for a use not listed on the label if, in the physician's clinical judgment, the off-label use is medically appropriate for the patient [7]. The FDA does not regulate the practice of medicine, and off-label prescribing accounts for approximately 20% of all outpatient prescriptions in the United States [8].

The PEARL trial (Participatory Evaluation of Aging with Rapamycin for Longevity), a randomized controlled trial published in Aging Cell in 2024, enrolled 150 healthy older adults (aged 50 to 85) to evaluate weekly low-dose rapamycin (5 mg once weekly) versus placebo over 48 weeks [9]. The trial reported that rapamycin was well tolerated at this dose, with no significant increase in serious adverse events compared to placebo. Visceral adipose tissue showed a reduction trend, though the primary endpoint of change in bone mineral density did not reach statistical significance.

Dr. Jonathan An, a co-investigator on the PEARL trial, noted: "The weekly dosing protocol was specifically chosen to minimize immunosuppressive effects while potentially preserving mTOR-related geroprotective activity." This distinction between daily immunosuppressive dosing and intermittent low-dose protocols is central to the current clinical conversation.

The Interventions Testing Program (ITP), funded by the National Institute on Aging, demonstrated that rapamycin extended median lifespan by 9% in male mice and 14% in female mice when initiated at 20 months of age (equivalent to roughly 60 human years) [10]. These results, published in Nature in 2009, catalyzed the off-label longevity interest that persists today.

Safety Profile at Immunosuppressive vs. Low Doses

The safety profile of sirolimus depends heavily on dosing regimen, duration, and whether it is combined with other immunosuppressants. Conflating the safety data from transplant-dose daily sirolimus with low-dose weekly protocols is a common error.

At transplant doses (daily, trough 5 to 24 ng/mL), common adverse effects include hyperlipidemia (occurring in 38 to 57% of patients), thrombocytopenia (13 to 30%), leukopenia, mouth ulcers, peripheral edema, and impaired wound healing [4][11]. Long-term immunosuppression increases risks of opportunistic infections and certain malignancies, particularly skin cancers and post-transplant lymphoproliferative disorder (PTLD).

At weekly low doses (1 to 6 mg once weekly), the adverse event profile appears milder. The PEARL trial (N=150) found no statistically significant difference in infection rates, lipid levels, or glucose parameters between the rapamycin and placebo groups over 48 weeks [9]. Mouth ulcers occurred in 12% of the rapamycin group versus 5% in the placebo group, a difference that was not statistically significant but clinically notable. A smaller randomized trial by Mannick et al. (2014, N=218) using the rapalog everolimus at low doses in older adults demonstrated improved immune response to influenza vaccination, suggesting that intermittent mTOR inhibition may enhance rather than suppress certain immune functions [12].

Dr. Matt Kaeberlein, a professor who has led dog aging studies with rapamycin, has stated: "The dose makes the poison, and the schedule makes the dose. Weekly rapamycin at 5 or 6 milligrams is pharmacokinetically and immunologically distinct from 2 milligrams daily."

Complete blood counts, fasting lipid panels, fasting glucose, and hepatic function should be monitored at baseline and at regular intervals (every 8 to 12 weeks during initiation) for any patient receiving sirolimus, regardless of indication or dose [1].

How to Legally Obtain Compounded Sirolimus

A patient in the United States who wants compounded sirolimus must follow a specific pathway. First, a licensed physician (MD or DO) must evaluate the patient and determine that sirolimus is medically appropriate. The physician writes a prescription specifying the dose, formulation, and frequency. This prescription is then sent to either a 503A compounding pharmacy (for a patient-specific preparation) or filled by a 503B outsourcing facility.

Insurance coverage for compounded medications is inconsistent. Most commercial insurers do not cover compounded drugs, and Medicare Part D generally excludes them. Patients should expect out-of-pocket costs. Generic sirolimus tablets (commercially manufactured) may be more cost-effective for standard strengths. A 30-day supply of generic sirolimus 1 mg tablets ranges from approximately $30 to $120 depending on pharmacy and insurance status, based on GoodRx pricing data.

Compounded formulations become relevant when a patient needs a non-standard strength (for example, 0.5 mg or 1.5 mg capsules for weekly dosing), a different delivery form (topical sirolimus for dermatologic applications like facial angiofibromas in tuberous sclerosis), or when a patient has allergies to inactive ingredients in the commercial product [13].

Telehealth prescribing of sirolimus is legal in most states, provided the prescriber holds a valid license in the patient's state and the prescriber-patient relationship meets state requirements. Some states impose additional restrictions on prescribing certain drug classes via telehealth, but sirolimus is not a controlled substance and does not fall under most such restrictions.

International Regulatory Status

Outside the United States, sirolimus regulation varies by jurisdiction. The European Medicines Agency (EMA) approved Rapamune in 2001 for renal transplant rejection prophylaxis under a centralized marketing authorization [14]. The EMA label closely mirrors the FDA label in terms of indications and warnings, though European prescribing patterns differ in some transplant protocols.

In the United Kingdom, sirolimus is available on the NHS for approved indications. Off-label prescribing in the UK is governed by General Medical Council (GMC) guidance, which permits it when no suitable licensed alternative exists and the prescriber is satisfied that sufficient evidence supports the off-label use.

Australia's Therapeutic Goods Administration (TGA) lists sirolimus on the Australian Register of Therapeutic Goods. The TGA allows authorized prescribers to access unapproved uses through the Special Access Scheme (SAS) or Authorised Prescriber pathway.

In Canada, sirolimus is approved by Health Canada. Compounding regulations fall under provincial pharmacy colleges, and rules vary by province. The distinction between 503A and 503B structures seen in the U.S. does not directly apply in Canada, where compounding is primarily regulated at the provincial level.

Patients traveling internationally should be aware that carrying sirolimus across borders requires documentation of the prescription and, in some countries, prior import approval.

Ongoing Clinical Trials and Regulatory Trajectory

Multiple clinical trials are evaluating rapamycin for non-transplant indications. The Dog Aging Project's TRIAD study (Test of Rapamycin In Aging Dogs) is a large-scale veterinary trial that may inform human dosing and safety data [15]. In humans, the VALIDATE trial is investigating rapamycin's effects on cardiovascular aging markers. The AgelessRx-sponsored RAPAMYCIN trial is evaluating effects on epigenetic age.

The FDA has not signaled any intention to restrict compounding of sirolimus. No FDA warning letters specific to sirolimus compounding have been issued as of May 2025. The drug's well-established generic availability, long safety track record (over 25 years post-approval), and lack of abuse potential all reduce regulatory risk.

Whether the FDA will eventually approve a rapamycin-based product for an aging-related indication depends on trial outcomes. The regulatory path would likely require a new NDA or supplemental NDA with Phase 3 data demonstrating efficacy for a specific aging-related endpoint. That process, even optimistically, would take 5 to 8 years from the start of a registrational trial. For now, legal access runs through off-label prescribing and compounding.

Patients considering rapamycin for any off-label purpose should work with a physician who monitors labs and adjusts dosing based on individual response, starting with a baseline comprehensive metabolic panel, CBC with differential, and fasting lipid panel before the first dose [1][9].